End Stage Renal Disease Market Trends

End Stage Renal Disease Market Trends

Rising number of patients suffering from end stage renal diseases (ESRD) is anticipated to drive the market trends. Chronic kidney disease is one of the leading cause of end stage renal diseases that affects a significant number of people. For instance, according to the CDC data, in 2022, around 35.5 million people in the U.S. were suffering from chronic kidney disease and is expected to increase in the near future. As CKD progresses, a portion of these patients eventually develop ESRD, leading to an increased demand for end stage renal diseases treatments. The global ageing population, and older adults are more susceptible to developing CKD and ESRD. Age-related changes in kidney function, coupled with comorbidities, contribute to the higher prevalence of ESRD among older individuals. The growth of the aging population is expected to contribute to the increasing number of ESRD patients.
 

There has been a growing emphasis on early detection and diagnosis of CKD and ESRD. Increased awareness among healthcare professionals and the general population has led to improved screening and diagnostic practices, resulting in more accurate identification of individuals with CKD and early-stage ESRD. This improved diagnosis contributes to the growing number of patients in need of ESRD treatments. Improved availability of dialysis facilities, healthcare insurance coverage, and the establishment of dedicated ESRD centers in underserved areas ensure that more patients can receive timely and appropriate treatment, driving market progress. Technological advancements in dialysis equipment, pharmaceuticals, and surgical techniques for kidney transplantation have improved treatment outcomes and patient survival rates.